ASH 2022 | Real-world multicenter study of caplacizumab in patients with acquired TTP
Eleni Gavriilaki
• 12 Dec 2022
Eleni Gavriilaki, MD, PhD, G Papanikolaou Hospital, Thessaloniki, Greece, shares some insights into a real-world multicenter study which evaluated caplacizumab in patients with acquired thrombotic thrombocytopenic purpura (aTTP). This study demonstrated that caplacizumab is safe and effective, although further real-world studies are needed to evaluate this agent. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Alexion: Honoraria; Omeros: Honoraria; Sanofi: Honoraria; Jazz: Research Funding; Gilead: Honoraria.
